Fujii Takaaki, Yanai Keiko, Tokuda Shoko, Nakazawa Yuko, Kurozumi Sasagu, Obayashi Sayaka, Yajima Reina, Hirakata Tomoko, Kuwano Hiroyuki
Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan
Division of Breast and Endocrine Surgery, Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.
Anticancer Res. 2017 Sep;37(9):5053-5056. doi: 10.21873/anticanres.11921.
The presence of ductal carcinoma in situ (DCIS) can increase the risk of developing an invasive ductal carcinoma (IDC), but it is difficult to predict what will occur if a DCIS is left untreated. We reported the usefulness of F-fluorodeoxyglucose positron emission tomography (FDG-PET) for DCIS, and that the presence of FDG uptake in the tumor could be considered a predictor of invasive potential in patients with DCIS. In this study, we retrospectively evaluated the clinicopathological features of DCIS by using FDG-PET findings, and we evaluated the possibility of using FDG-PET in DCIS cases as a biomarker of which lesions will go on to become invasive.
We investigated the cases of 185 consecutive patients with primary breast cancer who were diagnosed as having DCIS or IDC and underwent FDG-PET preoperatively.
We divided the cases into two groups on the basis of histology; DCIS vs. IDC (n=171). The DCIS cases were divided into two groups on the basis of FDG uptake in the primary tumor. Fourteen of the 185 patients (7.4%) were revealed to have a DCIS. The analysis revealed that the SUV and the number of cases not detected by FDG-PET were significantly different between the DICS and IDC groups. The extent of the primary tumor was not significantly different between the two groups. In six cases (42.9%) of the 14 DCIS cases, no FDG uptake was detected by FDG-PET. The extent of tumor did not significantly differ between the two groups. In addition, all six cases without FDG uptake were of the diffuse-spread type, without mass formation. All eight cases with mass formation had FDG uptake.
Our present findings suggest that the FDG-PET uptake reflects tumor burden or tumor density, which should be considered to be associated with the presence of invasion.
原位导管癌(DCIS)的存在会增加发生浸润性导管癌(IDC)的风险,但如果DCIS不进行治疗,很难预测会发生什么情况。我们报告了F-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)对DCIS的有用性,并且肿瘤中FDG摄取的存在可被视为DCIS患者浸润潜能的一个预测指标。在本研究中,我们通过使用FDG-PET检查结果回顾性评估DCIS的临床病理特征,并评估在DCIS病例中使用FDG-PET作为哪些病变将发展为浸润性病变的生物标志物的可能性。
我们调查了185例连续诊断为DCIS或IDC并术前接受FDG-PET检查的原发性乳腺癌患者的病例。
我们根据组织学将病例分为两组;DCIS组与IDC组(n = 171)。DCIS病例根据原发肿瘤中的FDG摄取情况分为两组。185例患者中有14例(7.4%)被诊断为DCIS。分析显示,DICS组和IDC组之间的SUV以及FDG-PET未检测到的病例数有显著差异。两组之间原发肿瘤的范围无显著差异。在14例DCIS病例中的6例(42.9%),FDG-PET未检测到FDG摄取。两组之间肿瘤范围无显著差异。此外,所有6例无FDG摄取的病例均为弥漫性扩散型,无肿块形成。所有8例有肿块形成的病例均有FDG摄取。
我们目前的研究结果表明,FDG-PET摄取反映了肿瘤负荷或肿瘤密度,应认为其与浸润的存在有关。